GlobeNewswire Inc.··Faruqi & Faruqi, LlpInovio Faces Securities Class Action Over Failed FDA Approval Strategy
Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.
INOstock declinesecurities class action